A 75-year-old man with long-standing type 2 diabetes and hypertension has persistent albuminuria and an eGFR of 40 mL/min/1.73 m². He is on an ACE inhibitor and SGLT2 inhibitor. According to KDIGO and Australian CKD updates, which additional agent may be considered to reduce CKD progression and cardiovascular events in appropriate patients with type 2 diabetes and CKD?